New drug tested to protect teens from severe genetic heart risk
NCT ID NCT04659863
Summary
This study tested a drug called inclisiran in teenagers (ages 12-17) with a rare, severe genetic condition that causes very high cholesterol from birth. The goal was to see if the drug was safe and effective at lowering 'bad' cholesterol (LDL-C) when added to their current standard treatments. For the first year, some participants received the drug and others received a placebo, and then all received the drug in the second year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL HYPERCHOLESTEROLEMIA - HOMOZYGOUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American University of Beirut Medical Center
Beirut, 1107 2020, Lebanon
-
Excel Medical Clinical Trials LLC
Boca Raton, Florida, 33434, United States
-
Hotel Dieu de France Hospital
El Achrafiyé, 166830, Lebanon
-
Metropolitan Hospital
Athens, 18547, Greece
-
Novartis Investigative Site
Québec, Quebec, G1V 4W2, Canada
-
Novartis Investigative Site
Bron, 69677, France
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
Amsterdam, 1105 AZ, Netherlands
-
Novartis Investigative Site
Istanbul, TUR, 34098, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
University General Hospital of Ioannina
Ioannina, GR, 455 00, Greece
Conditions
Explore the condition pages connected to this study.